{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T20:00:07Z","timestamp":1776024007459,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["lipidjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jacl.2025.04.186","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T07:07:33Z","timestamp":1744355253000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Achievement of low-density lipoprotein cholesterol thresholds in very high-risk atherosclerotic cardiovascular disease"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3092-6500","authenticated-orcid":false,"given":"Elisa A.","family":"Worledge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3735-5262","authenticated-orcid":false,"given":"Sarah J.","family":"Billups","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5084-6030","authenticated-orcid":false,"given":"Oliver J.","family":"Titus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0341-5140","authenticated-orcid":false,"given":"Joseph J.","family":"Saseen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.04.186_bib0001","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.04.186_bib0002","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.04.186_bib0003","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.04.186_bib0004","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2025.04.186_bib0005","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.04.186_bib0006","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.04.186_bib0007","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.04.186_bib0008","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jama.2023.4387","article-title":"It takes an average of 17 years for evidence to change practice-the burgeoning field of implementation science seeks to speed things up","volume":"329","author":"Rubin","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2025.04.186_bib0009","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","article-title":"High-intensity statin use among patients with atherosclerosis in the U.S","volume":"79","author":"Nelson","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.04.186_bib0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.amjcard.2022.10.033","article-title":"Bending the Cardiovascular Event Curve by Evaluating the Potential Impact of Achieving Low-Density Lipoprotein Cholesterol Goal Across a Large Health System Among Secondary Prevention Patients","volume":"186","author":"Shah","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2025.04.186_bib0011","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jacl.2025.04.186_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-200415","article-title":"Should anyone still be taking simvastatin 80 mg?","volume":"2013","author":"Tayal","year":"2013","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jacl.2025.04.186_bib0013","unstructured":"Pharmacy Quality Alliance. Frequently Asked Questions (FAQs) for the PQA Measure: \u201cProportion of Days Covered (PDC): 3 Rates\u201d in the Quality Rating System for the Health Insurance Marketplace. Available at: https:\/\/www.pqaalliance.org\/assets\/Measures\/QRS%20PDC%20FAQs%20080818.pdf. Accessed March 15, 2025."},{"key":"10.1016\/j.jacl.2025.04.186_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100336","article-title":"Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: a 2019 update","volume":"10","author":"Gu","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.04.186_bib0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/03007995.2023.2270901","article-title":"Clinical characteristics and treatment patterns in patients with atherosclerotic cardiovascular disease with hypercholesterolemia: a retrospective analysis of a large US real-world database cohort","volume":"40","author":"Lahoz","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2025.04.186_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0286376","article-title":"Trends in low-density lipoprotein cholesterol goal achievement and changes in lipid-lowering therapy after incident atherosclerotic cardiovascular disease: danish cohort study","volume":"18","author":"Ersboll","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2025.04.186_bib0017","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.04.186_bib0018","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jacc.2019.08.014","article-title":"Therapeutic inertia in cardiovascular disease prevention: time to move the bar","volume":"74","author":"Dixon","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.04.186_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028205","article-title":"US trends in cholesterol screening, lipid levels, and lipid-lowering medication use in US adults, 1999 to 2018","volume":"12","author":"Gao","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2025.04.186_bib0020","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.amepre.2022.10.010","article-title":"Trends in lipid-lowering prescriptions: increasing use of guideline-concordant pharmacotherapies, U.S., 2017\u20122022","volume":"64","author":"Sekkarie","year":"2023","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jacl.2025.04.186_bib0021","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","article-title":"Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.04.186_bib0022","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/j.amjmed.2019.04.002","article-title":"Association between lipid testing and statin adherence in the veterans affairs health system","volume":"132","author":"Jia","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2025.04.186_bib0023","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jacl.2020.09.001","article-title":"Early impact of the 2018 AHA\/ACC\/multisociety cholesterol guideline on lipid monitoring after statin initiation","volume":"14","author":"Tunoa","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.04.186_bib0024","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2023.02.003","article-title":"The importance of low-density lipoprotein cholesterol measurement and control as performance measures: a joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology","volume":"17","author":"Virani","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.04.186_bib0025","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005562","article-title":"Sex differences in the use of statins in community practice","volume":"12","author":"Nanna","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacl.2025.04.186_bib0026","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.numecd.2023.09.023","article-title":"LDL-cholesterol target levels achievement in high-risk patients: an (un)expected gender bias","volume":"34","author":"Berteotti","year":"2024","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacl.2025.04.186_bib0027","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036409","article-title":"Sex differences in nonadherence to secondary stroke prevention medications among patients with first-ever ischemic stroke","volume":"13","author":"Chen","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2025.04.186_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1047","article-title":"Assessment of sex disparities in nonacceptance of statin therapy and low-density lipoprotein cholesterol levels among patients at high cardiovascular risk","volume":"6","author":"Brown","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacl.2025.04.186_bib0029","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/S0140-6736(21)00684-X","article-title":"The Lancet women and cardiovascular disease commission: reducing the global burden by 2030","volume":"397","author":"Vogel","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.04.186_bib0030","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1161\/STROKEAHA.122.040536","article-title":"Lack of statin therapy and outcomes after ischemic stroke: a population-based study","volume":"54","author":"Aivo","year":"2023","journal-title":"Stroke"},{"key":"10.1016\/j.jacl.2025.04.186_bib0031","first-page":"685","article-title":"Patterns of statin use in a real-world population of patients at high cardiovascular risk","volume":"22","author":"Lin","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jacl.2025.04.186_bib0032","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1016\/j.jacc.2021.04.060","article-title":"Effectiveness of blood lipid management in patients with peripheral artery disease","volume":"77","author":"Hess","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.04.186_bib0033","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1358863X19871100","article-title":"Trends in statin utilization among adults with severe peripheral artery disease including critical limb ischemia in an integrated healthcare delivery system","volume":"25","author":"Reynolds","year":"2020","journal-title":"Vasc Med"},{"key":"10.1016\/j.jacl.2025.04.186_bib0034","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2015.09.025","article-title":"The role of the clinical pharmacist in the care of patients with cardiovascular disease","volume":"66","author":"Dunn","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.04.186_bib0035","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1016\/j.jacc.2024.04.034","article-title":"Randomized trial of a vascular care team vs education for patients with peripheral artery disease","volume":"83","author":"Hess","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.04.186_bib0036","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1377\/hlthaff.2020.01580","article-title":"Provider teams outperform solo providers in managing chronic diseases and could improve the value of care","volume":"40","author":"Pany","year":"2021","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jacl.2025.04.186_bib0037","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamacardio.2018.4936","article-title":"Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease","volume":"4","author":"Rodriguez","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2025.04.186_bib0038","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.amepre.2022.02.019","article-title":"Antihypertensive and statin medication adherence among medicare beneficiaries","volume":"63","author":"Jackson","year":"2022","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jacl.2025.04.186_bib0039","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/ehjcvp\/pvz079","article-title":"An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: barriers to be overcome","volume":"6","author":"Drexel","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacl.2025.04.186_bib0040","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jacc.2016.06.005","article-title":"Assessing the impact of medication adherence on long-term cardiovascular outcomes","volume":"68","author":"Bansilal","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.04.186_bib0041","article-title":"Primary nonadherence to statin medications: survey of patient perspectives","volume":"22","author":"Tarn","year":"2021","journal-title":"Prev Med Rep"},{"key":"10.1016\/j.jacl.2025.04.186_bib0042","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient","volume":"16","author":"Cheeley","year":"2022","journal-title":"J Clin Lipidol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425002636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425002636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T04:09:43Z","timestamp":1747454983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425002636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":42,"alternative-id":["S1933287425002636"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.04.186","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achievement of low-density lipoprotein cholesterol thresholds in very high-risk atherosclerotic cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.04.186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}